Shingles Vaccine Market Analysis, Growth, Business Competition and Future Opportunities 2034
Shingles Vaccine Market Growth, Size, Trends Analysis - By Product, By Vaccine Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Apr-2025 | Report ID: HLCA25110 | Pages: 1 - 244 | Formats*: |
| Category : Healthcare | |||
Shingles Vaccine Market Introduction and Overview
According to SPER Market Research, the Global Shingles Vaccine Market is estimated to reach USD 20.9 billion by 2034 with a CAGR of 15.58%.
The report includes an in-depth analysis of the Global Shingles Vaccine Market, including market size and trends, product mix, Applications, and supplier analysis. The rising incidence of herpes zoster is driving growth in the market for shingles vaccines. The aging of the world's population and compromised immune systems are its main causes. Government immunization campaigns, increased awareness, and the release of more potent recombinant vaccines like Shingrix are important motivators. Expanded vaccination coverage and improvements in healthcare infrastructure also contribute to market expansion. However, obstacles including exorbitant vaccine prices, restricted availability in low-income areas, and supply chain limitations prevent widespread adoption. Market penetration is further impacted by vaccine hesitancy and side effect worries. Notwithstanding these challenges, it is anticipated that enhanced distribution methods, strategic alliances, and ongoing research would boost market accessibility and growth.
By Product Insights
Shingles Vaccine is classified into three categories based on Product: Shingrix, Zostavax and SKYZoster. Shingrix's remarkable efficacy and lack of significant side effects allowed it to monopolize the market share. Since SkyZoster was recently approved for use in South Korean adults 50 years of age and older, the category is expected to grow at a profitable pace over the forecast period.
By Vaccine Type Insights
The market for Shingles Vaccine is segmented based on Vaccine Type, including Recombinant Vaccine, Live Attenuated Vaccine. A portion of the total income was ascribed to the improved disease prevention efficacy of recombinant vaccines, especially in the adult population, which made up the greatest percentage of the market. Over the course of the forecast period, the live attenuated vaccine market is expected to increase steadily due to rising awareness of infectious illnesses and growing support for vaccination campaigns, especially in developing nations.
By Regional Insights
The global market for shingles vaccines was dominated by North America. It is ascribed to a number of important elements, such as important industry participants, advantageous reimbursement regulations, and a notable vaccination uptake. The population's high level of awareness in the area and the strong vaccination recommendations further support the market's expansion throughout the course of the forecast period.
Market Competitive Landscape
Prominent firms in the worldwide shingles vaccine market are employing a range of strategies to improve their market share. In the quickly changing vaccination industry, these efforts seek to maintain competitiveness, enhance market share, and boost consumer satisfaction. Some of the key market players are GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc., CanSinoBIO, Vaccitech, Green Cross Corp, Geneone Life Science and SK Bioscience.
Recent Developments:
In April 2024, According to the ZOSTER-049 trial results published by GSK, Shingrix successfully prevented shingles in persons 50 years of age and above.
In February 2023, for an mRNA-based shingles vaccine, Pfizer and BioNTech conducted a Phase 1/2 experiment. Evaluating the safety, immunogenicity, and tolerability of their shingles vaccine candidates is the goal of the experiment.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Vaccine Type |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | GlaxoSmithKline plc., Pfizer Inc., Merck & Co., Inc., CanSinoBIO, Vaccitech, Green Cross Corp, Geneone Life Science, SK Bioscience. |
Key Topics Covered in the Report
- Global Shingles Vaccine Market Size (FY’2021-FY’2034)
- Overview of Global Shingles Vaccine Market
- Segmentation of Global Shingles Vaccine Market By Product (Shingrix, Zostavax, SKYZoster)
- Segmentation of Global Shingles Vaccine Market By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine)
- Statistical Snap of Global Shingles Vaccine Market
- Expansion Analysis of Global Shingles Vaccine Market
- Problems and Obstacles in Global Shingles Vaccine Market
- Competitive Landscape in the Global Shingles Vaccine Market
- Details on Current Investment in Global Shingles Vaccine Market
- Competitive Analysis of Global Shingles Vaccine Market
- Prominent Players in the Global Shingles Vaccine Market
- SWOT Analysis of Global Shingles Vaccine Market
- Global Shingles Vaccine Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Shingles Vaccine Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Shingles Vaccine Market
7. Global Shingles Vaccine Market, By Product 2021-2034 (USD Million)
7.1. Shingrix
7.2. Zostavax
7.3. SKYZoster
8. Global Shingles Vaccine Market, By Vaccine Type 2021-2034 (USD Million)
8.1. Recombinant Vaccine
8.2. Live Attenuated Vaccine
9. Global Shingles Vaccine Market, 2021-2034 (USD Million)
9.1. Global Shingles Vaccine Market Size and Market Share
10. Global Shingles Vaccine Market, By Region, 2021-2034 (USD Million)
.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
1.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. BioNTech SE
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. CanSinoBIO
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
1.3. CanSinoBIO
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Geneone Life Science
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. GlaxoSmithKline plc.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Green Cross Corp
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
.7. Merck & Co., Inc.
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Pfizer Inc.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. SK Bioscience
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Vaccitech
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Shingles Vaccine Market is projected to reach USD 20.9 by 2034, growing at a CAGR of 15.58% during the forecast period.
Shingles Vaccine Market size from 2025. The Market is expected to reach USD 20.9 by 2034, at a CAGR of 15.58% during the forecast period.
Shingles Vaccine Market CAGR of 15.58% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Shingles Vaccine Market Auxins Market size is USD 20.9 from 2025 to 2034.
Auxins Market covered By Coverage, By Product, By Vaccine Type
The North America is anticipated to have the highest Market share in the Shingles Vaccine Market .
GlaxoSmithKline plc., Pfizer Inc., Merck & Co., Inc., CanSinoBIO, Vaccitech, Green Cross Corp, Geneone Life Science, SK Bioscience.
The report includes an in-depth analysis of the Global Shingles Vaccine Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
